TRPS1 expression in 451 tubo-ovarian tumours: a potential
prognostic marker for high-grade serous carcinoma

J 2025

TRPS1 expression in 451 tubo-ovarian tumours: a potential prognostic marker for high-grade serous carcinoma

BUI, Quang Hiep; Ivana STRUZDZINSKADA; Michaela KENDALL BARTU; Romana MICHALKOVA; Jana DROZENOVA et al.

Základní údaje

Originální název

TRPS1 expression in 451 tubo-ovarian tumours: a potential prognostic marker for high-grade serous carcinoma

Autoři

Vydání

PATHOLOGY, AMSTERDAM, ELSEVIER, 2025, 0031-3025

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30109 Pathology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.000 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

TRPS1; IHC; immunohistochemistry; tubo-ovarian tumours; HGSC; high-grade serous carcinoma

Štítky

14110230, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 1. 2026 13:50, Mgr. Tereza Miškechová

Anotace

V originále

Trichorhinophalangeal syndrome type 1; transcriptional repressor GATA binding 1 (TRPS1), a member of the GATA transcription factor family, functions primarily as a transcriptional repressor. TRPS1 is frequently utilised as a diagnostic marker for breast carcinoma, although its specificity is lower than previously believed. Moreover, TRPS1 is expressed in various solid tumours originating from the skin, salivary glands, soft tissues, prostate, urothelium, and female genital tract. The current study evaluated the diagnostic and prognostic significance of TRPS1 in 451 primary tubo-ovarian tumours. The cohort included 94 high-grade serous carcinomas (HGSCs), 81 low-grade serous carcinomas (LGSCs), 31 micropapillary serous borderline tumours (mSBTs), 92 clear cell carcinomas (CCCs), 52 endometrioid carcinomas (ECs), 31 mucinous carcinomas (MCs), and 70 mucinous borderline tumours (MBTs). Immunohistochemical analysis was performed using tissue microarrays following standardised protocols. Clinical data were analysed to determine the prognostic relevance of TRPS1 expression. TRPS1 expression was detected in 47% of HGSCs, 44% of ECs, 35% of CCCs, 19% of LGSCs, and 29% of mSBTs with complete negativity in MC/MBT. TRPS1-negative HGSC cases had higher recurrence rates than those with positive staining. Furthermore, TRPS1 expression significantly correlated with improved metastasis-free survival in HGSC cases. These findings suggest that TRPS1 may serve as an independent prognostic marker for HGSC. Despite varying expression rates across primary tubo-ovarian carcinomas, the routine use of TRPS1 in the differential diagnosis seems to be limited, as other robust immunohistochemical markers are available for distinguishing the individual subgroups. Further research is needed to clarify the specific functions and clinical implications of TRPS1 in tubo-ovarian cancer.

Návaznosti

90233, velká výzkumná infrastruktura

Název: BBMRI.cz IV

Citovat

BUI, Quang Hiep; Ivana STRUZDZINSKADA; Michaela KENDALL BARTU; Romana MICHALKOVA; Jana DROZENOVA; Pavel FABIAN; Jitka HAUSNEROVÁ; Jan LACO; Radoslav MATEJ; Petr SKAPA; Marian SVAJDLER; Zuzana SPURKOVA; Gabor MEHES; Pavel DUNDR a Kristyna NDEMEJCOVA. TRPS1 expression in 451 tubo-ovarian tumours: a potential prognostic marker for high-grade serous carcinoma. PATHOLOGY. AMSTERDAM: ELSEVIER, 2025, roč. 57, č. 7, s. 831-837. ISSN 0031-3025. Dostupné z: https://doi.org/10.1016/j.pathol.2025.04.001.

@article{2548983,
   author = {Bui, Quang Hiep and Struzdzinskada, Ivana and Kendall Bartu, Michaela and Michalkova, Romana and Drozenova, Jana and Fabian, Pavel and Hausnerová, Jitka and Laco, Jan and Matej, Radoslav and Skapa, Petr and Svajdler, Marian and Spurkova, Zuzana and Mehes, Gabor and Dundr, Pavel and Ndemejcova, Kristyna},
   article_location = {AMSTERDAM},
   article_number = {7},
   doi = {https://doi.org/10.1016/j.pathol.2025.04.001},
   keywords = {TRPS1; IHC; immunohistochemistry; tubo-ovarian tumours; HGSC; high-grade serous carcinoma},
   language = {eng},
   issn = {0031-3025},
   journal = {PATHOLOGY},
   title = {TRPS1 expression in 451 tubo-ovarian tumours: a potential prognostic marker for high-grade serous carcinoma},
   url = {https://www.sciencedirect.com/science/article/pii/S0031302525001771?via%3Dihub},
   volume = {57},
   year = {2025}
}

TY  - JOUR
ID  - 2548983
AU  - Bui, Quang Hiep - Struzdzinskada, Ivana - Kendall Bartu, Michaela - Michalkova, Romana - Drozenova, Jana - Fabian, Pavel - Hausnerová, Jitka - Laco, Jan - Matej, Radoslav - Skapa, Petr - Svajdler, Marian - Spurkova, Zuzana - Mehes, Gabor - Dundr, Pavel - Ndemejcova, Kristyna
PY  - 2025
TI  - TRPS1 expression in 451 tubo-ovarian tumours: a potential prognostic marker for high-grade serous carcinoma
JF  - PATHOLOGY
VL  - 57
IS  - 7
SP  - 831-837
EP  - 831-837
PB  - ELSEVIER
SN  - 00313025
KW  - TRPS1
KW  - IHC
KW  - immunohistochemistry
KW  - tubo-ovarian tumours
KW  - HGSC
KW  - high-grade serous carcinoma
UR  - https://www.sciencedirect.com/science/article/pii/S0031302525001771?via%3Dihub
N2  - Trichorhinophalangeal syndrome type 1; transcriptional repressor GATA binding 1 (TRPS1), a member of the GATA transcription factor family, functions primarily as a transcriptional repressor. TRPS1 is frequently utilised as a diagnostic marker for breast carcinoma, although its specificity is lower than previously believed. Moreover, TRPS1 is expressed in various solid tumours originating from the skin, salivary glands, soft tissues, prostate, urothelium, and female genital tract. The current study evaluated the diagnostic and prognostic significance of TRPS1 in 451 primary tubo-ovarian tumours. The cohort included 94 high-grade serous carcinomas (HGSCs), 81 low-grade serous carcinomas (LGSCs), 31 micropapillary serous borderline tumours (mSBTs), 92 clear cell carcinomas (CCCs), 52 endometrioid carcinomas (ECs), 31 mucinous carcinomas (MCs), and 70 mucinous borderline tumours (MBTs). Immunohistochemical analysis was performed using tissue microarrays following standardised protocols. Clinical data were analysed to determine the prognostic relevance of TRPS1 expression. TRPS1 expression was detected in 47% of HGSCs, 44% of ECs, 35% of CCCs, 19% of LGSCs, and 29% of mSBTs with complete negativity in MC/MBT. TRPS1-negative HGSC cases had higher recurrence rates than those with positive staining. Furthermore, TRPS1 expression significantly correlated with improved metastasis-free survival in HGSC cases. These findings suggest that TRPS1 may serve as an independent prognostic marker for HGSC. Despite varying expression rates across primary tubo-ovarian carcinomas, the routine use of TRPS1 in the differential diagnosis seems to be limited, as other robust immunohistochemical markers are available for distinguishing the individual subgroups. Further research is needed to clarify the specific functions and clinical implications of TRPS1 in tubo-ovarian cancer.
ER  -

BUI, Quang Hiep; Ivana STRUZDZINSKADA; Michaela KENDALL BARTU; Romana MICHALKOVA; Jana DROZENOVA; Pavel FABIAN; Jitka HAUSNEROVÁ; Jan LACO; Radoslav MATEJ; Petr SKAPA; Marian SVAJDLER; Zuzana SPURKOVA; Gabor MEHES; Pavel DUNDR a Kristyna NDEMEJCOVA. TRPS1 expression in 451 tubo-ovarian tumours: a potential prognostic marker for high-grade serous carcinoma. \textit{PATHOLOGY}. AMSTERDAM: ELSEVIER, 2025, roč.~57, č.~7, s.~831-837. ISSN~0031-3025. Dostupné z: https://doi.org/10.1016/j.pathol.2025.04.001.

Přehled o publikaci